Abstract
Asthma is currently defined as a chronic inflammatory disease of the airways. The goals of proper asthma therapy, as put forward in recent guidelines, are not only to prevent symptoms and exacerbations, but also to allow for normal activity levels and maintain pulmonary function within near normal limits1. In order to achieve these goals, a stepwise therapeutic approach has been adopted. This is based on obvious avoidance measures, in combination with pharmacological intervention. Medication used for asthma treatment is broadly categorized into two classes: long-term medication, used to achieve and maintain control of the disease, and immediate relief medication, used to treat acute symptoms and exacerbations.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
GINA report. International Consensus report on diagnosis and management of asthma. US Dept Health and Human Services, 1992.
Lam S, Chan H, Leriche JC, Chan-Yeung M, Salad H. Release of leukotrienes in patients with bronchial asthma. J Allergy Clin Immunol. 1988; 81: 711–17.
Adelroth E, Morris MM, Hargreave FE, O’Byrne P. Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls. N Engl J Med. 1986; 315: 480–4.
Drazen JM, Austen KF. Leukotrienes and airway responses. Am Rev Resp Dis. 1987; 136: 985–98.
Laitinen LA, Laitinen A, Haahtela T, Vilkka V, Spur BW, Lee TH. Leukotriene E4and granulocytic infiltration into asthmatic airways. Lancet. 1993; 341: 989–90.
Hay DWP, Torphy TJ, Undem BJ. Cysteinyl leukotrienes in asthma: Old mediators up to new tricks. TiPS. 1995; 16: 304–09.
Cohen P, Noveral JP, Bhala A, Nunn SE, Herrick DJ, Grunstein MM. Leukotriene D4facilitates airway smooth muscle cell proliferation via modulation of the IGF axis. Am J Physiol. 1995; 269: L151–7.
Gaddy JN, Margolskee DJ, Bush RK, Williams VC, Busse WW. Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma. Am Rev Resp Dis. 1992; 146: 358–63.
Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet. 1991; 337: 1062–3.
Reiss TF, Sorkness CA, Stricker W, et al. Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax. 1997; 52: 45–8.
Israel E, Juniper EF, Callaghan JT, et al. Effect of a leukotriene antagonist, LY 171883 on cold air-induced bronchoconstriction in asthmatics. Am Rev Resp Dis. 1989; 140: 1348–53.
Manning PJ, Watson RM, Margolskee DJ, Williams VC, Schwartz JI, O’Byrne PM. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. N Engl J Med 1990; 323: 1736–9.
Finnerty JP, Wood-Baker R, Thomson H, Holgate ST. Role of leukotrienes in exercise-induced asthma. Am Rev Resp Dis. 1992; 145: 746–9.
Taylor IK, O’Shaughnessy KM, Fuller RW, Dollery CT. Effect of cysteinyl-leukotriene receptor antagonist ICI 204,219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects. Lancet. 1991; 337: 690–4.
Rasmussen JB, Eriksson L-O, Margolskee DJ, Tagari P, Williams VC, Andersson K-E. Leukotriene D4receptor blocker inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J Allergy Clin Immunol. 1992; 90: 193–201.
Kane GC, Pollice M, Kim C-J, et al. A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. J Allergy Clin Immunol. 1996; 97: 646–54.
Wenzel SE, Trudeau JB, Kaminsky DA, Cohn J, Martin RJ, Westcott JY. Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. Am J Resp Crit Care Med. 1995; 152: 897–905.
Calhoun WJ, Williams KL, Simonson SG, Lavins BJ. Effect of zafirlukast (AccolateTM) on airway inflammation after segmental allergen challenge in patients with mild asthma. Am J Respir Crit Care Med. 1997; 155: A662.
Leff JA, Pizzichini E, Efthimiadis A, et al. Effect of montelukast (MK-0476) on airway eosinophilic inflammation in mildly uncontrolled asthma: A randomized placebo-controlled trial. Am J Resp Crit Care Med. 1997; 155: A977.
Liu MC, Dube LM, Lancaster J, Zileuton Study Group. Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: A 6-month randomized multicenter trial. J Allergy Clin Immunol. 1996; 98: 859–71.
Calhoun WJ, Weisberg SC, Faiferman I, Stober PW. Pranlukast (UltairTM) is effective in improving asthma: results of a I2-week, multicenter, dose-ranging study. J Allergy Clin Immunol. 1997; 99. S318.
Spector SL, Smith LJ, Glass M. Effect of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. Am J Resp Crit Care Med. 1994; 150: 618–23.
Tashkin DP, Nelson HS, Cohn J, Hanby LA, Miller CJ. Efficacy and safety of zafirlukast (Accolate) in patients with mild to moderate asthma. Am J Resp Crit Care Med. 1996; 153: A534.
Suissa S, Dennis R, Ernst P, Sheehy O, Wooddauphine. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma - a randomized double-blind, placebo-controlled trial. Ann Intern Med. 1997; 126: 177.
Reiss TF, Chervinsky P, Edwards T, et al. Montelukast Study Group. Montelukast (MK-0476), a Cys LT1 receptor antagonist, improves asthma outcomes over a 3-month treatment period. Am J Resp Crit Care Med. 1997; 155: A662.
Sahn S, Galant S, Murray J, et al., on behalf of the Ultair Study Group. Pranlukast (UltairTM) improves FEV1, in patients with asthma: results of a 12-week multicenter study vs Nedocromil. Am J Resp Crit Care Med..1997; 155: A665.
Nathan RA, Glass M, Snader L. Effects of 13 weeks of treatment with ICI 204,219 (AccolateTM) or cromolyn sodium (IntalTM) in patients with mild to moderate asthma. J Allergy Clin Immunol. 1995; 95: S388.
Wenzel P, Chervinsky P, Kerwin E, Silvers W, Faiferman I, Dubb J. Oral pranlukast (UltairTM) vs inhaled beclomethasone: Results of a 12-week trial in patients with asthma. Am J Resp Crit Care Med. 1997; 155: A203.
Tamaoki J, Kondo M, Sakai N, et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. Am J Resp Crit Care Med. 1997; 155: 1235–40.
Bateman ED, Holgate ST, Binks SM, Tams IP. A multicenter study to assess the steroid-sparing potential of AccolateTM (Zafirlukast; 20mg BD). Allergy. 1995; 50: P-0709.
Laitinin LA, Zetterstrom O, Holgate ST, Binks SM, Whitney JG. Effects of AccolateTM (Zafirlukast; 20mg BD) in permitting reduced therapy with inhaled steroids: a multicenter trial in patients with doses of inhaled steroid optimised between 800 and 2000 mcg per day. Allergy. 1995; 50: P-0710.
O’Connor BJ, Godard P, Dube LM, Swanson LI, Rountree LV. The effect of 5-lipoxygenase inhibitor, zileuton, plus low-dose inhaled beclomethasone compared to higher dose beclomethasone alone in patients with asthma. Am J Resp Crit Care Med. 1996; 153: A803.
Christie PE, Tagari P, Ford-Hutchinson AW, et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin sensitive asthmatic subjects. Am Rev Resp Dis. 1991; 143: 1025–9.
Arm JS, O’Hickey S, Spur BW Lee TH. Airway responsiveness to histamine and leukotriene E4 in subjects with aspirin-induced asthma. Am Rev Resp Dis. 1987; 140: 148–53.
Dahlén B, Margolskee DJ, Zetterstrom O, Dahlén S-E. Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thorax. 1993; 48: 1205–10.
Israel E, Fischer AR, Rosenberg MA, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Resp Dis. 1993; 148: 1447–51.
Kuna P, Malmstrom K, Dahlén S-E, et al. Montelukast (MK-0476), a CysLT1 antagonist, improves asthma control in aspirin-intolerant asthmatic patients. Am J Resp Crit Care Med. 1997; 155: A975
The British Guidelines on asthma management 1995. Review and position statement. Thorax. 1997; 52: SI-21.
Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institutes of Health. February 1997.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Kips, J.C., Pauwels, R.A. (1998). How to use anti-leukotrienes in the treatment of asthma. In: Rodger, I., Botting, J., Dahlén, SE. (eds) Leukotrienes. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-4880-1_10
Download citation
DOI: https://doi.org/10.1007/978-94-011-4880-1_10
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6045-5
Online ISBN: 978-94-011-4880-1
eBook Packages: Springer Book Archive